Brain aging and Parkinson's disease: New therapeutic approaches using drug delivery systems
| Autor: | M.M. Carmona-Abellán, Carlos Rodríguez-Nogales, María J. Blanco-Prieto, Elisa Garbayo, Maria-Rosario Luquin |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
0301 basic medicine
Levodopa Aging Proteasome Endopeptidase Complex Parkinson's disease Dopamine Disease Pharmacology Bioinformatics General Biochemistry Genetics and Molecular Biology Antioxidants 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Drug Delivery Systems Glial cell line-derived neurotrophic factor Medicine Humans Nerve Growth Factors Alpha-synuclein biology business.industry MPTP Obstetrics and Gynecology Brain Parkinson Disease Genetic Therapy medicine.disease LRRK2 Mitochondria Oxidative Stress 030104 developmental biology Neuroprotective Agents chemistry Drug delivery Dopamine Agonists biology.protein alpha-Synuclein Lewy Bodies business Lysosomes Peptides 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Maturitas. 84 |
| ISSN: | 1873-4111 |
| Popis: | The etiology and pathogenesis of Parkinson's disease (PD) is unknown, aging being the strongest risk factor for brain degeneration. Understanding PD pathogenesis and how aging increases the risk of disease would aid the development of therapies able to slow or prevent the progression of this neurodegenerative disorder. In this review we provide an overview of the most promising therapeutic targets and strategies to delay the loss of dopaminergic neurons observed both in PD and aging. Among them, handling alpha-synuclein toxicity, enhancing proteasome and lysosome clearance, ameliorating mitochondrial disruptions and modifying the glial environment are so far the most promising candidates. These new and conventional drugs may present problems related to their labile nature and to the difficulties in reaching the brain. Thus, we highlight the latest types of drug delivery system (DDS)-based strategies for PD treatment, including DDS for local and systemic drug delivery. Finally, the ongoing challenges for the discovery of new targets and the opportunities for DDS-based therapies to improve and efficacious PD therapy will be discussed. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect